| Literature DB >> 28132905 |
Daniel F Carr1, Seyoum Ayehunie2, Andrea Davies3, Carrie A Duckworth4, Stephanie French3, Neil Hall5, Syed Hussain6, Howard R Mellor7, Alan Norris3, B Kevin Park3, Alexander Penrose3, D Mark Pritchard4, Chris S Probert4, Shashi Ramaiah8, Claire Sadler9, Michael Schmitt10, Alison Shaw11, James E Sidaway12, Robert G Vries13, Matthew Wagoner14, Munir Pirmohamed3.
Abstract
Adverse drug reactions affecting the gastrointestinal (GI) tract are a serious burden on patients, healthcare providers and the pharmaceutical industry. GI toxicity encompasses a range of pathologies in different parts of the GI tract. However, to date no specific mechanistic diagnostic/prognostic biomarkers or translatable pre-clinical models of GI toxicity exist. This review will cover the current knowledge of GI ADRs, existing biomarkers and models with potential application for toxicity screening/monitoring. We focus on the current gaps in our knowledge, the potential opportunities and recommend that a systematic approach is needed to identify mechanism-based GI biomarkers with potential for clinical translation.Entities:
Keywords: Adverse drug reaction; Biomarker; Gastrointestinal; In vitro; In vivo; Toxicity
Mesh：
Substances：
Year: 2017 PMID： 28132905 DOI： 10.1016/j.pharmthera.2017.01.002
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310